Theravance Biopharma buy klostergang
Start price
01.12.18
/
50%
€25.26
Target price
04.11.21
€34.28
Performance (%)
-41.40%
End price
17.06.21
€14.80
Summary
This prediction ended on 17.06.21 with a price of €14.80. Massive losses of -41.40% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Theravance Biopharma | 0.714% | 0.714% | 55.801% | 38.235% |
| iShares Core DAX® | -1,34 % | 1,40 % | 2,62 % | 51,69 % |
| iShares Nasdaq 100 | -2,99 % | 2,18 % | 33,89 % | 89,73 % |
| iShares Nikkei 225® | -2,90 % | 4,32 % | 53,00 % | 64,74 % |
| iShares S&P 500 | -2,32 % | 1,48 % | 22,86 % | 64,72 % |
Comments by klostergang for this prediction
In the thread Theravance Biopharma diskutieren
klostergang stimmt der Buy-Einschätzung von marge zu
klostergang stimmt am 01.12.2018 der Buy-Einschätzung von marge mit dem Kursziel 55$ zu.
Überschrift: TBPH: Revefenacin for Chronic Obstructive Pulmonary disease [COPD]